Company Overview of Epizyme, Inc.
Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops epigenetic therapies for cancer patients. Its proprietary product platform creates small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases (HMTs). The company has two HMTs inhibitors in clinical development for the treatment of patients with cancers. It is conducting a Phase I/II clinical trial of EPZ-6438, an inhibitor that targets the EZH2 HMT for the treatment of non-Hodgkin lymphoma and advanced solid tumors, including INI1-deficient tumors, such as synovial sarcoma and malignant rhabdoid tumors; and two Phase 1 clinical trials of EPZ-5676, an inhibitor targeting the DO...
400 Technology Square
Cambridge, MA 02139
Founded in 2007
Key Executives for Epizyme, Inc.
Chief Executive Officer, President, Secretary and Director
Total Annual Compensation: $652.8K
Chief Scientific Officer and President of Research
Total Annual Compensation: $531.7K
Chief Development Officer
Total Annual Compensation: $163.7K
Compensation as of Fiscal Year 2014.
Epizyme, Inc. Key Developments
Epizyme Seeks Acquisitions
May 4 15
Epizyme, Inc. (NasdaqGS:EPZM) intends to use the net proceeds from the sale of any securities offered under this prospectus to fund clinical development of our product candidates, to fund preclinical development and research to advance our pipeline and expand our product platform and for general corporate purposes unless otherwise indicated in the applicable prospectus supplement. General corporate purposes may include the acquisition of companies or businesses, repayment and refinancing of debt, if any, working capital and capital expenditures.
Epizyme, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015
Apr 28 15
Epizyme, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported collaboration revenue of $911,000 against $13,391,000 a year ago. Operating loss was $61,377,000 against $6,912,000 a year ago. Net loss was $61,326,000 or $1.75 per basic and diluted share against $6,884,000 or $0.22 per basic and diluted share a year ago. The decline in collaboration revenue primarily reflects the substantial completion of certain components of the company’s research obligations under its collaborations.
Epizyme, Inc. to Report Q1, 2015 Results on Apr 28, 2015
Apr 21 15
Epizyme, Inc. announced that they will report Q1, 2015 results at 4:30 PM, US Eastern Standard Time on Apr 28, 2015
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|